TABLE 5.
Tac concentration/dose between baseline and period of azole co-therapy.
| Triazole | Before/after co-therapy | During azole co-therapy | p | |
|---|---|---|---|---|
| Voriconazole | Tac concentration (ng/μL) | 5.31 ± 3.06 | 8.37 ± 4.39 | <0.001 |
| Tac dose (mg/day) | 2.86 ± 2.25 | 1.46 ± 1.19 | <0.001 | |
| Tac C/D (ng/μL/mg) | 4.86 ± 6.35 | 10.62 ± 10.57 | <0.001 | |
| Posaconazole | Tac concentration (ng/μL) | 6.01 ± 2.79 | 7.63 ± 3.64 | 0.021 |
| Tac dose (mg/day) | 3.21 ± 2.44 | 2.55 ± 2.17 | 0.356 | |
| Tac C/D (ng/μL/mg) | 3.36 ± 3.53 | 5.30 ± 4.42 | 0.027 |
C/D, dose-corrected through concentration; Tac, tacrolimus.